Voyager Therapeutics (VYGR) Tops Q1 EPS by 9c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/4/2026
- S&P 500, Dow set for lower open after jobs report fuels rate-hike bets
- US nonfarm payrolls surge in August; unemployment rate steady at 4.1%
- BofA's Hartnett says stay long commodities and gold as 'policy panic' works
- Oil heads for weekly gain as US-Iran fighting resumes; diesel hits record high
- TikTok owner ByteDance said to secure $29.6bn loan for AI push
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
- After-Hours Movers: WDAY, ADSK, S, RBRK, MRVL, ULTA, GAP, AFRM
- After-Hours Movers: NVDA, CRM, SNPS, CRWD, OKTA, NTNX
Voyager Therapeutics Provides First Quarter 2016 Investor Update
May 12, 2016 7:00 AM EDTEnrollment Completed in 2nd Cohort of Ongoing Phase 1b Clinical Trial of VY-AADC01 in Advanced Parkinsons Disease
VY-AADC01 Interim Phase 1b Results to be Presented at 20th International Congress of Parkinsons Disease & Movement Disorders in June 2016
CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today reported its first quarter 2016 financial results and provided an update on its advanced Parkinsons disease program, VY-AADC01. The Company also... More
Voyager Therapeutics to Present at Upcoming Investor Conferences
May 11, 2016 8:01 AM EDTCAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Voyager Therapeutics, Inc. (NASDAQ: VYGR), a clinical-stage gene therapy company developing life-changing treatments for severe diseases of the central nervous system (CNS), today announced that company management will present at the following upcoming investor conferences in New York City:
Piper Jaffray GenomeRx SymposiumDate: Tuesday, May 17, 2016Â Panel 1 Title: Thinking Smart About CNS Targeting Gene... More